SMA
PBAXU

Sage Mountain Advisors’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

Sage Mountain Advisors’s Portfolio PBAXU Stock Details PBAXU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-35,610
Closed -$358K – 479
2022
Q2 		$358K Sell
35,610
-10,580
-23% -$107K 0.06% 286
2022
Q1 		$465K Sell
46,190
-18,600
-29% -$188K 0.07% 272
2021
Q4 		$653K Buy
+64,790
New +$656K 0.08% 246

Other funds holding PBAXU

SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $46.4M AUM 13.94% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

Sage Mountain Advisors's PBAXU Position: Q3 2022 in Review

Sage Mountain Advisors sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q3 2022, closing a stake of 35,610 shares — an estimated $358K sold.

Sage Mountain Advisors first reported a position in PBAXU in Q4 2021 and held it in 3 quarters. The position peaked at $653K in Q4 2021. 21 funds tracked by Wall St. Rank hold PBAXU as of Q3 2022.

  • Sage Mountain Advisors reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q3 2022 after selling out during the quarter.
  • Sage Mountain Advisors sold 35,610 Phoenix Biotech Acquisition Corp. Unit shares in Q3 2022, an estimated $358K.
  • Sage Mountain Advisors first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q4 2021 and held it in 3 quarters.
  • Sage Mountain Advisors's Phoenix Biotech Acquisition Corp. Unit position peaked at $653K in Q4 2021.
  • 21 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q3 2022.

Based on Sage Mountain Advisors's 13F filing for Q3 2022, filed 31 Oct 2022.